SCHEMBL24101581

SCHEMBL24101581

CN1CCc2[nH]c3ncc(Cl)cc3c2CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
CHRNA7 P36544 1/20 0.38
DRD2 P14416 5/20 0.38
DRD1 P21728 5/20 0.38
DRD5 P21918 5/20 0.38
DRD3 P35462 5/20 0.38
DRD4 P21917 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
MEN1 O00255 1/20 0.38
GMNN O75496 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA1D P25100 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
MTOR P42345 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340105 1.00 KDM4E (0.38) KDM4ECHRNA7DRD2DRD1DRD5
SCHEMBL12480316 0.90 CHRNA7 (0.50) KDM4ECHRNA7CYP1A2CYP2D6CYP2C9
SCHEMBL26017356 0.83 HTR6 (0.36) KDM4ECHRNA7DRD2DRD1DRD5
SCHEMBL26017449 0.83 DRD2 (0.44) KDM4ECHRNA7DRD2DRD1DRD5
SCHEMBL26017354 0.83 CHEK1 (0.37) KDM4ECHRNA7DRD2DRD1DRD5
SCHEMBL407032 0.81 ACHE (0.46)
SCHEMBL26017341 0.81 USP2 (0.48) KDM4ECHRNA7DRD2DRD1DRD5
SCHEMBL24101759 0.80 TNIK (0.36) MEN1CYP3A4KMT2A
SCHEMBL30339781 0.79 MAP3K12 (0.37) BAZ2B
SCHEMBL24101589 0.79 MAP3K12 (0.37) BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
WO-2021252691-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF GAP43, GRIN2A, GRIN2C KDM4E 2586/4885CHRNA7 62/4885DRD2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.